Quantum Genomics: Half-Year Results and Financial Strategies

Quantum Genomics has published its financial results for the first half of 2024, marked by a significant deterioration. The absence of turnover and a net loss of €8.2 million highlight the company's financial difficulties. This situation is mainly attributed to the acquisition of its subsidiary ExactCure, specialized in digital health.

The exceptional expenses related to the integration of ExactCure impacted the operating result, which amounts to -1.1 million euros. In addition, the depreciation of ExactCure shares and the difficulties in generating new contracts worsened the financial situation of Quantum Genomics.

Faced with tight cash flow, the company received financial support from Akkadian Partners Fund, thus avoiding compulsory liquidation. New governance initiatives were put in place to stabilise the company, with the hope of finding additional financing.